Concepedia

Kai Lin

KL

Statistics

Publications

41

Citations

3.4K

H-Index

28

Active since

1974

Affiliations

Novartis (United States)(Current)

Vertex Pharmaceuticals (United States)

Novartis (Switzerland)

Atea Pharmaceuticals (United States)

University of Pennsylvania

Kai Lin is an author at Novartis (United States) specializing in molecular virology, virology, and life sciences.

ORCID

Publications per year

1974–2023

41

Publications

41

An adenosine nucleoside inhibitor of dengue virus

Zheng Yin, Yen‐Liang Chen, Wouter Schul et al. · Proceedings of the National Academy of Sciences · 2009 · 396 citations · Full text

, , +17

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni, Susan J. Almquist, Randal A. Byrn et al. · Antimicrobial Agents and Chemotherapy · 2006 · 387 citations · Full text

, , +17

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Kai Lin, Ann D. Kwong · Journal of Biological Chemistry · 2004 · 289 citations · Full text

, , +13

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Cynthia A. Gates, B. Govinda Rao et al. · Journal of Biological Chemistry · 2005 · 216 citations · Full text

, , +17

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

Kai Lin, Robert B. Perni, Ann D. Kwong et al. · Antimicrobial Agents and Chemotherapy · 2006 · 200 citations · Full text

, , +17

1–5 of 41